Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is a name to know if you are not already familiar with the company. Cannabics is a legitimate player in new cannabis cancer research. CNBX has upside where many others have potential in this space because of their team. Furthermore, CNBX has been trading upward this week as it seems more is understood about their technology and its potential.
Recently, CNBX filed the first of a cluster of patent applications with the US Patent office covering their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body. This news was well received and the market again responded by pushing the stock price up.
Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) bills itself as a U.S based public company dedicated to the development of Personalized Anti-Cancer and Palliative treatments.
The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital.
CNBX’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Its flagship product is Cannabics SR, a long-acting medical cannabis capsule that shows therapeutic effects as a palliative care therapy for cancer patients.
The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Find out when $CNBX stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Dr. Moran Grinberg, VP of R&D of Cannabics Pharmaceuticals said “Our new integrated approach will allow patients and practitioners to receive a more accurate, personalized result pertaining to their particular individual status. Today we are at the midst of a technological revolution that combines algorithms predicting medical treatment that is based on cumulative clinical data. Therefore, we believe that the integration of multi-system data derived from our screening technologies will provide a comprehensive overview on the patient`s condition”.
Separately, CNBX’s financial position has been growing over time. This is easily seen in their revenue position which currently stands at $1,571 rising from $1,243 in the previous quarter, a 26% jump. Management attributed this to more effective marketing methods for their products during their period.
They also had lower costs over this period as compared to the same period last year with the costs standing at $139,000 and $337,000 in research and development and sales, general and administrative expenses (SGA) respectively in February 2017 as compared to $223,000 and $427,000 in February 2016. Management has adopted a cost reduction strategy as they aim at netting a profit in the current year and moving onwards.
Holding a market capitalization of $108.86M, CNBX has an ability to enter a space that has lucrative potential. Solutions in the cancer space for cannabis are for real and if ever an FDA approval was to come down, it would be a gamechanger. For continuing coverage on shares of $CNBX stock, as well as our other breakout picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $CNBX, either long or short, and we have not been compensated for this article.